Paul Reidy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul Reidy has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aoibhlinn O’ Toole
Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
1 shared publication - Brendan O'KElly
Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland
1 shared publication - Cora McNally
Department of Infectious Diseases, Beaumont Hospital, D09 V2NO Dublin, Ireland
1 shared publication - Eoghan de Barra
Department of International Health and Tropical Medicine, Royal College of Surgeons Ireland (RCSI), University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland
1 shared publication - John Caird
Neurosurgery, Beaumont Hospital, Dublin, Ireland
1 shared publication - Samuel McConkey
Infectious Diseases Service, Beaumont Hospital, D09 V2N0 Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 25 May 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (6) , 557
Isavuconazole Treatment of Spinal Cord Invasive Aspergillosis Guided by Cerebrospinal Fluid (1,3)-β-d-Glucan Levels in a Patient with Low Interferon-Gamma and Ulcerative Colitis
This case highlights the use of (1,3)-beta-d glucan to direct treatment of a cervical spinal cord Aspergillus fumigatus infection in a 22-year-old woman immunocompromised due to steroid and anti-TNF therapy in the context of ulcerative colitis and interferon gamma deficiency. A 4-year treatment course requiring neurosurgical intervention on four occasions and prolonged antifungal therapy, including isavuconazole, resulted in clinical cure with a corresponding decrease in CSF beta-d-glucan to <30 pg/mL. Serum and CSF galactomannan levels were not elevated at any point during the clinical course.
- 25 May 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (6) , 557
Open AccessIsavuconazole Treatment of Spinal Cord Invasive Aspergillosis Guided by Cerebrospinal Fluid (1,3)-β-d-Glucan Levels in a Patient with Low Interferon-Gamma and Ulcerative Colitis
This case highlights the use of (1,3)-beta-d glucan to direct treatment of a cervical spinal cord Aspergillus fumigatus infection in a 22-year-old woman immunocompromised due to steroid and anti-TNF therapy in the context of ulcerative colitis and interferon gamma deficiency. A 4-year treatment course requiring neurosurgical intervention on four occasions and prolonged antifungal therapy, including isavuconazole, resulted in clinical cure with a corresponding decrease in CSF beta-d-glucan to <30 pg/mL. Serum and CSF galactomannan levels were not elevated at any point during the clinical course.